Overview

A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Status:
Enrolling by invitation
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This study is a single center, open lable and fixed sequence test conducted in healthy subjects to evaluate the pharmacokinetic effects of Itraconazole and Rifampicin on a single dose of ABSK021 Oral administration. It is planned to enroll 32 healthy subjects and assign them to two parallel test groups, Part A (ABSK021 combined with Itraconazole) and Part B (ABSK021 combined with Rifampicin).
Phase:
Phase 1
Details
Lead Sponsor:
Abbisko Therapeutics Co, Ltd
Treatments:
Itraconazole
Rifampin